美国 · SEC FORM 4
Keros Therapeutics, Inc.
KROS · Nasdaq · CIK 0001664710 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
4 qualifying P purchase groups
当前 180 天评分窗口
18 同一窗口内观察到的 Form 4 交易行
8 sales · 6 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-08-17 · BIENAIME JEAN JACQUES · $10.3K
为什么没有活跃信号？
买入活动存在
近期买入4 qualifying line group(s)
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
BIENAIME JEAN JACQUESDirector
●○●●●
Newton Charles W.Director
▼▼
Farzan NimaDirector
○▼
Knowles JuliusDirector
○▼
Seth AlpnaDirector
○▼
GRAY MARY ANNDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
合资格买方1
买入集中度100%最大买方： BIENAIME JEAN JACQUES · $41.6K
聚集买入 · 15天1 insider峰值活动： 2026-05-15–2026-05-15
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-08-17 · BIENAIME JEAN JACQUES.
近期 Form 4 活动
6买入
12卖出
14其他 Form 4 交易行
29SEC 申报 · 365天
买入4 qualifying P line(s) · 180 days
卖出8 sale line(s) · 仅供背景
其他6 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,149,418
- 上期报告
- 1,342,620
- 日均成交量
- 205,020
- 回补天数
- 5.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 10.27 | USD 10,270 | SEC 申报 ↗ |
| 2026-07-15 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 10.61 | USD 10,610 | SEC 申报 ↗ |
| 2026-06-15 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 10.19 | USD 10,190 | SEC 申报 ↗ |
| 2026-05-15 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 10.58 | USD 10,580 | SEC 申报 ↗ |
| 2026-04-15 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 11.70 | USD 11,700 | SEC 申报 ↗ |
| 2026-03-09 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 2,000 | USD 11.21 | USD 22,420 | SEC 申报 ↗ |
| 2025-04-09 | ADAR1 Capital Management GP, LLC; ADAR1 Capital Management, LLC; ADAR1 Partners, LP; Schneeberger Daniel | 买入 (P) | Common Stock | 934,258 | USD 10.13 | USD 9,465,655 | SEC 申报 ↗ |
| 2020-11-17 | Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd.; Pontifax Management 4 G.P. (2015) Ltd. | 买入 (P) | Common Stock | 60,000 | USD 50.00 | USD 3,000,000 | SEC 申报 ↗ |
| 2020-11-17 | Nussbaum Ran; Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd. | 买入 (P) | Common Stock | 60,000 | USD 50.00 | USD 3,000,000 | SEC 申报 ↗ |
| 2020-11-17 | Kariv Tomer; Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd. | 买入 (P) | Common Stock | 60,000 | USD 50.00 | USD 3,000,000 | SEC 申报 ↗ |
| 2020-04-13 | Knowles Julius | 买入 (P) | Common Stock | 1,191 | USD 20.98 | USD 24,987 | SEC 申报 ↗ |
| 2020-04-13 | Seehra Jasbir | 买入 (P) | Common Stock | 20,000 | USD 16.00 | USD 320,000 | SEC 申报 ↗ |
| 2020-04-13 | Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd.; Pontifax Management 4 G.P. (2015) Ltd. | 买入 (P) | Common Stock | 437,499 | USD 16.00 | USD 6,999,984 | SEC 申报 ↗ |
| 2020-04-13 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 375,200 | USD 16.00 | USD 6,003,200 | SEC 申报 ↗ |
| 2020-04-13 | Nussbaum Ran | 买入 (P) | Common Stock | 437,499 | USD 16.00 | USD 6,999,984 | SEC 申报 ↗ |
Form 4 申报证据
32 transaction lines in the latest 365-day window; 521 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Tanini Annita | 卖出 (S) | Common Stock | 1,224 | USD 10.29 | USD 12,595 | SEC 申报 ↗ |
| 2026-08-18 | Newton Charles W. | 卖出 (S) | Common Stock | 551 | USD 10.30 | USD 5,675 | SEC 申报 ↗ |
| 2026-08-18 | Lerner Lorena Raquel | 卖出 (S) | Common Stock | 3,568 | USD 10.29 | USD 36,715 | SEC 申报 ↗ |
展开近期 Form 4 证据 (29 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Tanini Annita | 卖出 (S) | Common Stock | 1,224 | USD 10.29 | USD 12,595 | SEC 申报 ↗ |
| 2026-08-18 | Newton Charles W. | 卖出 (S) | Common Stock | 551 | USD 10.30 | USD 5,675 | SEC 申报 ↗ |
| 2026-08-18 | Lerner Lorena Raquel | 卖出 (S) | Common Stock | 3,568 | USD 10.29 | USD 36,715 | SEC 申报 ↗ |
| 2026-08-18 | Cho Esther | 卖出 (S) | Common Stock | 4,485 | USD 10.29 | USD 46,151 | SEC 申报 ↗ |
| 2026-08-17 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 10.27 | USD 10,270 | SEC 申报 ↗ |
| 2026-07-15 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 10.61 | USD 10,610 | SEC 申报 ↗ |
| 2026-07-01 | Prener Anne | 奖励／授予 (A) | Common Stock | 13,786 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-15 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 10.19 | USD 10,190 | SEC 申报 ↗ |
| 2026-06-11 | Newton Charles W. | 卖出 (S) | Common Stock | 550 | USD 10.04 | USD 5,522 | SEC 申报 ↗ |
| 2026-06-04 | Knowles Julius | 卖出 (S) | Common Stock | 2,625 | USD 10.73 | USD 28,166 | SEC 申报 ↗ |
| 2026-06-04 | Farzan Nima | 卖出 (S) | Common Stock | 2,625 | USD 10.73 | USD 28,166 | SEC 申报 ↗ |
| 2026-06-04 | Seth Alpna | 卖出 (S) | Common Stock | 2,625 | USD 10.72 | USD 28,140 | SEC 申报 ↗ |
| 2026-06-03 | Seth Alpna | 奖励／授予 (A) | Common Stock | 7,142 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Knowles Julius | 奖励／授予 (A) | Common Stock | 7,142 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | GRAY MARY ANN | 奖励／授予 (A) | Common Stock | 7,142 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Farzan Nima | 奖励／授予 (A) | Common Stock | 7,142 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | BIENAIME JEAN JACQUES | 奖励／授予 (A) | Common Stock | 7,142 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-15 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 10.58 | USD 10,580 | SEC 申报 ↗ |
| 2026-04-15 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 1,000 | USD 11.70 | USD 11,700 | SEC 申报 ↗ |
| 2026-04-02 | Seehra Jasbir | 期权行权／转换 (M) | Common Stock | 55,000 | USD 0.30 | USD 16,500 | SEC 申报 ↗ |
| 2026-03-09 | Newton Charles W. | 奖励／授予 (A) | Common Stock | 13,215 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-09 | BIENAIME JEAN JACQUES | 买入 (P) | Common Stock | 2,000 | USD 11.21 | USD 22,420 | SEC 申报 ↗ |
| 2026-02-19 | Seehra Jasbir | 卖出 (S) | Common Stock | 7,015 | USD 16.17 | USD 113,433 | SEC 申报 ↗ |
| 2026-02-18 | Regnante Keith | 卖出 (S) | Common Stock | 4,739 | USD 16.35 | USD 77,483 | SEC 申报 ↗ |
| 2026-02-18 | Lerner Lorena Raquel | 卖出 (S) | Common Stock | 3,873 | USD 16.35 | USD 63,324 | SEC 申报 ↗ |
| 2026-02-18 | Cho Esther | 卖出 (S) | Common Stock | 4,745 | USD 16.35 | USD 77,581 | SEC 申报 ↗ |
| 2025-11-21 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | D (D) | Common Stock | 214,522 | USD 17.75 | USD 3,807,766 | SEC 申报 ↗ |
| 2025-11-21 | Knowles Julius | D (D) | Common Stock | 322,021 | USD 17.75 | USD 5,715,873 | SEC 申报 ↗ |
| 2025-11-21 | GORDON CARL L | D (D) | Common Stock | 214,522 | USD 17.75 | USD 3,807,766 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | KROS |
| CIK | 0001664710 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 521 transaction lines from 2020-04-13 to 2026-08-18 41 P purchase lines · 352 S sale lines · 128 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.